Positive phase II clinical data for vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease presented at conference

Vupanorsen, an investigational antisense therapy being developed to treat patients with certain CVDs met the primary endpoint (significant reductions in triglyceride levels) and multiple secondary endpoints compared to placebo in this dose finding study (n=105).


Biospace Inc.